Volume 28, Issue 4 (10-2025)
J Arak Uni Med Sci 2025, 28(4): 316-319 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mobedi M. Oral Baclofen Withdrawal: A Case Report of an Iranian Infant with Gastroesophageal Reflux Disease, Presenting with Seizure. J Arak Uni Med Sci 2025; 28 (4) :316-319
URL: http://jams.arakmu.ac.ir/article-1-7838-en.html
URL: http://jams.arakmu.ac.ir/article-1-7838-en.html
Assistant Professor, Department of Pediatric Neurology, Arak University of Medical Sciences, Arak, Iran , dmobedi95@gmail.com
Abstract: (301 Views)
Introduction: Baclofen, a GABA-B receptor agonist, acts on presynaptic and postsynaptic neurons in the central and peripheral nervous systems. Baclofen withdrawal causes activation of dopamine and noradrenergic receptors. Symptoms usually develop in 1 to 3 days of cessation, including altered mental status, worsening of spasticity, fever, weakness, autonomic instability, seizures, neuroleptic malignant syndrome, neuropsychiatric manifestations, and a life-threatening state. It can be observed in patients taking oral or intrathecal baclofen following sudden discontinuation or dose reduction. Baclofen is a commonly used medicine in patients with muscle spasticity. It can also relieve gastroesophageal reflux disease (GERD) symptoms.
Case Report: Here, we report a four-month-old Iranian boy with normal neurodevelopment who was referred to the pediatric emergency department due to extreme irritability, intense crying, poor feeding, insomnia, staring, and a seizure episode. He was admitted to the pediatric intensive care unit, with initial assessment of vital signs (mild fever, tachycardia, tachypnea), laboratory tests (anemia), brain CT (computed tomography), and EEG (electroencephalogram), which were non-diagnostic. Meningitis also was ruled out. He was started on serum and antibiotic therapy and intravenous phenobarbital, but symptoms and signs did not completely improve, and the patient was irritable and his poor feeding was continued. Further history revealed GERD treated with oral baclofen for three months, which had been discontinued three days prior to admission. Baclofen was restarted at the previous dosage, resulting in rapid symptomatic improvement. The patient was transferred to the neurology department and then discharged in good general condition with oral baclofen and phenobarbital. Phenobarbital was tapered and discontinued after two weeks without seizure recurrence.
Conclusions: After four months of follow-up, the patient was in normal condition. To the author's knowledge, no cases of seizures after discontinuation of baclofen have been reported in Iranian infants under six months of age with GERD.
Case Report: Here, we report a four-month-old Iranian boy with normal neurodevelopment who was referred to the pediatric emergency department due to extreme irritability, intense crying, poor feeding, insomnia, staring, and a seizure episode. He was admitted to the pediatric intensive care unit, with initial assessment of vital signs (mild fever, tachycardia, tachypnea), laboratory tests (anemia), brain CT (computed tomography), and EEG (electroencephalogram), which were non-diagnostic. Meningitis also was ruled out. He was started on serum and antibiotic therapy and intravenous phenobarbital, but symptoms and signs did not completely improve, and the patient was irritable and his poor feeding was continued. Further history revealed GERD treated with oral baclofen for three months, which had been discontinued three days prior to admission. Baclofen was restarted at the previous dosage, resulting in rapid symptomatic improvement. The patient was transferred to the neurology department and then discharged in good general condition with oral baclofen and phenobarbital. Phenobarbital was tapered and discontinued after two weeks without seizure recurrence.
Conclusions: After four months of follow-up, the patient was in normal condition. To the author's knowledge, no cases of seizures after discontinuation of baclofen have been reported in Iranian infants under six months of age with GERD.
References
1. Albright AL, Barron WB, Fasick MP, Polinko P, Janosky J . Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA. 1993;270(20):2475-7. pmid: 8230625
2. Allerton CA, Boden PR, Hill RG. Actions of the GABAB agonist,(−)‐baclofen, on neurones in deep dorsal horn of the rat spinal cord in vitro. Br J Pharmacol. 1989;96(1):29-38. doi: 10.1111/j.1476-5381.1989.tb11780.x pmid: 2924075
3. Arabpour E, Khoshdel S, Akhgarzad A, Abdi M, Tabatabaie N, Alijanzadeh D, et al. Baclofen as a therapeutic option for gastroesophageal reflux disease: A systematic review of clinical trials. Front Med (Lausanne). 2023;10:997440. doi: 10.3389/fmed.2023.997440 pmid: 36873860
4. Cunningham J, Jelic S. Baclofen withdrawal: a cause of prolonged fever in the intensive care unit. Anaesthesia and intensive care. 2005;33(4):534-7. doi: 10.1177/0310057X0503300421 pmid: 16119501
5. Alvis BD, Sobey CM. Oral baclofen withdrawal resulting in progressive weakness and sedation requiring intensive care admission. Neurohospitalist. 2017;7(1):39-40. doi: 10.1177/1941874416637404 pmid: 28042369
6. Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract. 2014;2014:307805. doi: 10.1155/2014/307805 pmid: 25389436
7. Vadlamudi NB, Hitch MC, Dimmitt RA, Thame KA. Baclofen for the treatment of pediatric GERD. J Pediatr Gastroenterol Nutr. 2013;57(6):808-12. doi: 10.1097/MPG.0b013e3182a2747b pmid: 23838820
8. Zhang Q, Lehmann A, Rigda R, Dent J, Holloway R. Control of transient lower oesophageal sphincter relaxations and reflux by the GABAB agonist baclofen in patients with gastro-oesophageal reflux disease. Gut. 2002;50(1):19-24. doi: 10.1136/gut.50.1.19 pmid: 11772961
9. Coffey RJ, Edgar TS, Francisco GE, Graziani V, Meythaler JM, Ridgely PM, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 2002;83(6):735-41. doi: 10.1053/apmr.2002.32820 pmid: 12048649
10. Saulino M, Anderson DJ, Doble J, Farid R, Gul F, Konrad P, et al. Best practices for intrathecal baclofen therapy: troubleshooting. Neuromodulation. 2016;19(6):632-41. doi: 10.1111/ner.12467 pmid: 27434299
11. Cardoso AL, Quintaneiro C, Seabra H, Teixeira C. Cardiac arrest due to baclofen withdrawal syndrome. BMJ Case Rep . 2014;2014:bcr2014204322. doi: 10.1136/bcr-2014-204322 PMID: 24827663
12. Watve S, Sivan M, Raza W, Jamil F. Management of acute overdose or withdrawal state in intrathecal baclofen therapy. Spinal Cord. 2012;50(2):107-11. doi: 10.1038/sc.2011.112 pmid: 22006082
13. Paul V, Righter K, Kim E, Nadherny W. Severe hyperthermia due to oral baclofen withdrawal. BMJ Case Rep. 2020;13(9):e234710. doi: 10.1136/bcr-2020-234710 pmid: 32994264
14. Farid R. Problem-solving in patients with targeted drug delivery systems. Mo Med. 2017;114(1):52-6. pmid: 30233102
15. Sampathkumar P, Scanlon PD, Plevak DJ. Baclofen withdrawal presenting as multiorgan system failure. Anesth Analg. 1998;87(3):562-3. doi: 10.1097/00000539-199809000-00011 pmid: 9728828
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
